Breaking bacterial resistance to frontline antibiotics


Friday, 14 January, 2022

Breaking bacterial resistance to frontline antibiotics

Researchers at The Peter Doherty Institute for Infection and Immunity, The University of Queensland (UQ), Griffith University, The University of Adelaide and St. Jude Children’s Research Hospital have discovered how to repurpose a molecule called PBT2 — originally developed as a potential treatment for disorders such as Alzheimer’s, Parkinson’s and Huntington’s diseases — to break bacterial resistance to commonly used frontline antibiotics. Their discovery may soon see the comeback of readily available and cheap antibiotics, such as penicillin and ampicillin, as effective weapons in the fight against antibiotic resistance.

Rising numbers of bacterial infections — such as pneumonia, tuberculosis, gonorrhoea and salmonellosis — are becoming harder to treat as the antibiotics used against them are becoming less effective. The researchers found a way break this bacterial drug resistance and developed a therapeutic approach to use of ampicillin to treat drug-resistant bacterial pneumonia caused by Streptococcus pneumoniae in a mouse model of infection. Their results were published in the journal Cell Reports.

The breakthrough was sparked when Professor Christopher McDevitt, a laboratory head at the Doherty Institute, had been conducting research into bacterial antibiotic resistance using zinc ionophores. This led to collaborations with UQ’s Professor Mark Walker and Griffith University’s Professor Mark von Itzstein.

“We knew that some ionophores, such as PBT2, had been through clinical trials and shown to be safe for use in humans,” Prof von Itzstein said.

Prof Walker said, “As a group, we realised that if we could repurpose these safe molecules to break bacterial resistance and restore antibiotic efficacy, this would be a pathway to a therapeutic treatment. What we had to do was show whether PBT2 broke bacterial resistance to antibiotic treatment without leading to even greater drug resistance.”

Crucially important was the research from Prof McDevitt’s group that led to knowing how and where treatment could be most effective. Prof McDevitt explained, “We knew from earlier research that the immune system uses zinc as an innate antimicrobial to fight off infection. So we developed our therapeutic approach with PBT2 to use the body’s antimicrobial zinc to break antibiotic resistance in the invading bacteria.

“This rendered the drug-resistant bacteria susceptible to the antibiotic ampicillin, restoring the effectiveness of the antibiotic treatment in the infected animals.”

According to Prof von Itzstein, the discovery has the potential to provide a cost-effective and readily available treatment to life-threatening infections such as community-acquired bacterial pneumonia, which poses a serious public health risk. Prof McDevitt said the researchers are now working towards collecting the data required for a clinical trial of PBT2 in combination with antibiotics.

“We also want to find other antibiotic-PBT2 combinations that have therapeutic potential for treatment of other bacterial infections,” he said.

“Our work shows that this simple combination therapy is safe, but the combinations require testing in clinical trials. What we need now is to move forward with further testing and pharmacology.”

Image credit: ©stock.adobe.com/au/Sasa Komlen

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

TGA approves Novavax vaccine, oral treatments for COVID-19

The TGA has granted provisional approval for the first two oral treatments for COVID-19 in...

Skin infections confirmed as a cause of rheumatic fever

A major breakthrough in further understanding acute rheumatic fever shows that skin infections...

Link found between brain structure, genetics and chronic pain

Genetic differences contribute to both an increased risk of certain chronic pain types and a...


  • All content Copyright © 2022 Westwick-Farrow Pty Ltd